Scott Kinlay MBBS, PhD
Adjunct Associate Professor, Cardiovascular Medicine
Associate Professor, Medicine
72 E. Concord Street scott.kinlay@va.gov
Sections
Cardiovascular Medicine
Biography
Dr. Scott Kinlay is the Chief of Cardiology and Director of Vascular Medicine at the VA Boston Healthcare System, West Roxbury Campus. He is affiliated with Brigham and Women's Hospital. He is currently licensed to practice medicine in Massachusetts.
Other Positions
Education
Medicine-Surgery, MBBS, University of Sydney
Epidemiology, PhD, University of Newcastle
Publications
Kroshian G, Joseph J, Kinlay S, Peralta AO, Hoffmeister PS, Singh JP, Yuyun MF. Atrial fibrillation and risk of adverse outcomes in heart failure with reduced, mildly reduced, and preserved ejection fraction: A systematic review and meta-analysis. J Cardiovasc Electrophysiol. 2024 Apr; 35(4):715-726. PMID: 38348517.
Published on 1/24/2024Shapeton AD, Kinlay S, Geahchan C, Ortoleva J. Perioperative Apixaban: Bleeding, Clotting, or Both? J Cardiothorac Vasc Anesth. 2024 Apr; 38(4):865-867. PMID: 38368165.
Published on 1/23/2024Belyayev L, Stock EM, Hattler B, Bakaeen FG, Kinlay S, Quin JA, Haime M, Biswas K, Zenati MA. Complete Coronary Revascularization and Outcomes in Patients Who Underwent Coronary Artery Bypass Grafting: Insights from The REGROUP Trial. Am J Cardiol. 2024 Apr 15; 217:127-135. PMID: 38266796.
Published on 11/17/2023Gikandi A, Habertheuer A, Stock EM, Hirji S, Kinlay S, Tsao A, Butala N, Biswas K, Zenati MA. Anatomical SYNTAX score and major adverse cardiac events following CABG in the REGROUP trial. J Cardiol. 2024 May; 83(5):348-350. PMID: 37977259.
Published on 10/19/2023Yuyun MF, Joseph J, Erqou SA, Kinlay S, Echouffo-Tcheugui JB, Peralta AO, Hoffmeister PS, Boden WE, Yarmohammadi H, Martin DT, Singh JP. Persistence of significant secondary mitral regurgitation post-cardiac resynchronization therapy and survival: a systematic review and meta-analysis : Mitral regurgitation and mortality post-CRT. Heart Fail Rev. 2024 Jan; 29(1):165-178. PMID: 37855988.
Published on 9/25/2023Kinlay S. Long-Term Patient Outcomes After Femoropopliteal Peripheral Vascular Intervention in Patients With Intermittent Claudication. JACC Cardiovasc Interv. 2023 Sep 25; 16(18):2335. PMID: 37758389.
Published on 9/4/2023Evans P, Sobieszczyk P, Eisenhauer AC, Ostrowski S, Todoran TM, Kinlay S. Risk of Mortality Related to Recurrent Limb Events After Endovascular Revascularization of the Superficial Femoral Artery for Peripheral Artery Disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) Study. Am J Cardiol. 2023 Oct 15; 205:425-430. PMID: 37666014.
Published on 7/28/2023Almarzooq ZI, Al-Roub NM, Kinlay S. Antithrombotic treatment following percutaneous coronary intervention in patients with high bleeding risk. Curr Opin Cardiol. 2023 Nov 01; 38(6):515-520. PMID: 37522805.
Published on 5/21/2023Kinlay S, Sobieszczyk P, Eisenhauer AC, Ostrowski S, Todoran TM. Patient and limb outcomes 10 years after endovascular revascularization of the superficial femoral artery for peripheral artery disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) study. Vasc Med. 2023 Aug; 28(4):290-298. PMID: 37211818.
Published on 1/16/2023Kinlay S, Young MM, Sherrod R, Gagnon DR. Long-Term Outcomes and Duration of Dual Antiplatelet Therapy After Coronary Intervention With Second-Generation Drug-Eluting Stents: The Veterans Affairs Extended DAPT Study. J Am Heart Assoc. 2023 Jan 17; 12(2):e027055. PMID: 36645075.